CAS: 1360053-81-1

Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).

Spebrutinib besylate is a salt form of spebrutinib, which is a small molecule tyrosine kinase inhibitor. It has been shown to inhibit the proliferation of lymphocytes in vitro and in vivo. The mechanism by which spebrutinib besylate inhibits cell proliferation is not fully understood, but it may be due to inhibition of tyrosine kinases and their downstream signaling pathways. Spebrutinib besylate also has potential antineoplastic activity, as it targets family members that are involved in the development and progression of lymphoma.